Oramed Pharmaceuticals Inc
$ 3.73
7.80%
25 Feb - close price
- Market Cap 148,634,000 USD
- Current Price $ 3.73
- High / Low $ 3.76 / 3.42
- Stock P/E 3.73
- Book Value 4.98
- EPS 1.00
- Next Earning Report 2026-03-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE 0.24 %
- 52 Week High 3.76
- 52 Week Low 1.70
About
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
Analyst Target Price
$3.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-17 | 2025-08-14 | 2025-05-07 | 2025-03-04 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-06 | 2023-11-10 | 2023-08-10 | 2023-05-11 |
| Reported EPS | 0 | 0.15 | 0.31 | -0.19 | -0.2552 | -0.48 | 0.26 | 0.04 | 0.33 | -0.08 | -0.03 | -0.08 |
| Estimated EPS | -0.08 | -0.04 | -0.01 | -0.05 | 0.02 | 0.04 | 0.01 | 0.02 | -0.12 | -0.08 | -0.1 | -0.26 |
| Surprise | 0.08 | 0.19 | 0.32 | -0.14 | -0.2752 | -0.52 | 0.25 | 0.02 | 0.45 | 0 | 0.07 | 0.18 |
| Surprise Percentage | 100% | 475% | 3200% | -280% | -1376% | -1300% | 2500% | 100% | 375% | 0% | 70% | 69.2308% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.0 |
| Currency | USD |
Previous Dividend Records
| Jan 2026 | |
|---|---|
| Payment Date | 2026-01-26 |
| Amount | $0.25 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORMP
2026-02-20 21:30:52
Scilex Holding Company (SCLX) has issued a new warrant to Oramed Pharmaceuticals Inc. for 100,000 shares at an exercise price of $20.00. This agreement defers a 2025 amortization payment on Scilex's senior secured convertible notes, with the payment ultimately made in November 2025. The warrant, exercisable immediately and expiring in December 2029, includes protective clauses like anti-dilution adjustments and ownership caps.
2026-02-14 13:57:33
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) experienced a significant 57.8% increase in short interest in January, reaching 644,912 shares, which represents about 2.0% of its outstanding shares. Despite this, several institutional investors either initiated or increased their positions, with overall institutional ownership at approximately 12.73%. The company, which is developing an oral insulin capsule in Phase 3 trials, has a market cap of $129.35M and recently paid a $0.25 dividend.
2026-02-04 11:58:46
Oramed Pharmaceuticals, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, has achieved a remarkable 60.85% return over the last six months, leading market performance. In contrast, Federated Hermes, a Small Cap firm, saw a 7.25% return, while Robinhood Markets, a Large Cap player, experienced a decline of -12.84%. This highlights the diverse performance trends and varying dynamics within different market segments.
2026-02-02 19:43:00
Nano Dimension recently adopted a "poison pill" shareholder rights agreement, making hostile takeovers prohibitively expensive. This move comes shortly after Oramed Pharmaceuticals and its CEO disclosed a 5% stake in Nano Dimension, indicating their intention to push for strategic and governance changes. Nano Dimension, a 3D printing technology company, is currently undergoing a restructuring with new CEO Ofir Baharav aiming for profitability.
2026-01-23 12:57:37
Oramed Pharmaceuticals Inc. is undergoing a significant market reassessment following a strategic pivot and planned capital return to shareholders. The company's stock declined after trading ex-dividend, with a $0.25 per share payout scheduled for January 26, 2026, financed partly by an $18 million payment from Scilex Holdings. Oramed has transformed its investment proposition by transferring its POD technology to Lifeward for a 49.9% equity stake, shifting from a drug developer to an investor in a diversified biotech firm.
2026-01-18 08:28:03
Oramed Pharmaceuticals (NASDAQ:ORMP) experienced a significant 34.6% increase in short interest in December, reaching 424,089 shares, which represents about 1.3% of the company's float. The days-to-cover ratio is currently 3.4 days. Institutional investors, including BML Capital Management LLC, have also increased their holdings in the biotechnology company, which focuses on oral drug delivery systems.
